Passiflora Edulis Flower.

Passiflora edulis flowers carry the same C-glycosyl flavones, vitexin and isovitexin, that give Passiflora incarnata its calming profile. Their effects on normal evening relaxation run in the same direction and add.

Both carry flavones with affinity for the benzodiazepine recognition site of the GABA-A receptor. Combining them concentrates activity at one target.

Lemon balm slows GABA breakdown through GABA transaminase inhibition while passiflora flavones act at the receptor. The two ends of the pathway pair without overlapping.

The flower and the fruit come from the same species and share the vitexin-type flavone family, though the fruit also carries the polyphenol and fibre fraction. A formula holding both is stacking one plant's chemistry.

Melatonin sets circadian timing through its own receptors, a mechanism unrelated to flavone modulation of GABA-A. The two address different parts of normal sleep onset.

Valerian and passionflower appear together in calming botanical blends across European herbal practice. Both are described as acting on GABAergic signalling, so the combination is expected to be additive rather than complementary. Anyone already taking something sedating should count the two together rather than separately.

L-theanine shifts cortical activity toward alpha rhythm and is used to support a settled, unhurried state during waking hours. Passiflora flavones are described as acting at the GABA-A benzodiazepine site in vitro. The two arrive at a similar destination by different routes, which is why they are often placed in the same daytime calm formula.

Magnesium is a physiological NMDA receptor blocker and a positive modulator at GABA-A, and glycine itself is an inhibitory neurotransmitter at its own receptor. Passiflora flavones are proposed to work at a different site on the same receptor family. The pairing is common in evening formulas and the rationale is mechanistic rather than trial-based.

Glycine is an inhibitory neurotransmitter in the brainstem and spinal cord and also lowers core temperature at gram-level intakes. Passiflora contributes flavones described as GABA-A active in vitro. Nothing has measured the two together, so read the pairing as mechanistic.

Supplemental GABA reaches its receptors poorly because central nervous system penetration is limited, and much of its reported effect is attributed to enteric signalling. Passiflora flavones are lipophilic enough to be discussed as central modulators. Pairing them is a formulation habit built on mechanism, not on a combination study.

5-HTP is decarboxylated to serotonin and feeds melatonin synthesis downstream. Passiflora extracts carry trace beta-carboline alkaloids that inhibit monoamine oxidase in vitro, so in principle the two touch the same amine pool from opposite ends. The alkaloid content of flower material is low, and this interaction is worth naming rather than assuming it is large.

Tryptophan is the dietary starting point for serotonin and then melatonin. Passiflora contributes flavones and trace beta-carbolines that act further downstream on the same signalling. The pairing rests on biochemistry rather than on a trial of the combination.

Apigenin is one of the flavones that occurs naturally in Passiflora flower material, so adding isolated apigenin raises the same molecule the extract already delivers. Apigenin binds the benzodiazepine site of GABA-A with low affinity in vitro. Because the extract already contributes some, the combined flavone intake is what matters, not either input alone.

Quercetin and the Passiflora C-glycosyl flavones belong to the same flavonoid family and are handled by overlapping phase II conjugation enzymes. Co-dosing raises total flavonoid load and can saturate the same sulfotransferase and UGT routes. This is a shared-metabolism observation, not evidence of a larger effect.

Rutin is a flavonol glycoside that gut bacteria deglycosylate before the aglycone is absorbed, which is the same route the C-glycosides in Passiflora depend on. Both therefore rise and fall with the state of the microbiota. Formulators pair them for antioxidant claims, and the pharmacokinetic overlap is the more concrete point.

Luteolin sits alongside apigenin in the flavone class and shares the same low-affinity benzodiazepine-site binding described in vitro. Passiflora flower extracts already deliver related flavones, so the two stack on one another. Read it as mechanistic overlap rather than a tested combination.

Ascorbate regenerates oxidised flavonoid radicals back to their reduced form in solution, which is why the two are often formulated together. The relevance is largely to the stability of the finished product and to in vitro antioxidant assays. It does not by itself say anything about what happens in a person.

Ashwagandha is used to support the normal stress response and is repeatedly placed in the same evening or calm formulas as Passiflora. The mechanisms differ: one is discussed at the hypothalamic-pituitary-adrenal axis, the other at GABA-A. Nothing has measured the flower extract with ashwagandha specifically.

Honokiol and magnolol from magnolia bark are positive allosteric modulators at GABA-A in preclinical work. Passiflora flavones are described at a different site on the same receptor. Combined, they should be counted as one sedating input rather than two independent ones.

Piperine inhibits UDP-glucuronosyltransferase and several CYP enzymes, which raises exposure to many co-dosed polyphenols. Passiflora flavone aglycones are glucuronidated heavily after absorption, so piperine could plausibly raise their circulating levels. No one has measured this pairing, and a higher exposure is a change in dose, not automatically a better outcome.

Phospholipid complexation is a standard way to carry poorly soluble flavonoid aglycones across the intestinal membrane. Lecithin also serves as a flow and dispersion aid in dried botanical powders. The role here is delivery and manufacturability rather than any activity of its own.